Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis

Hepatology

Volumn 35, Issue 6, 2002, Pages 1341-1350

  Pascale, Rosa M ^a   Simile, Maria M ^a   De Miglio, Maria R ^a   Muroni, Maria R ^a   Calvisi, Diego F ^a   Asara, Giuseppina ^a   Casabona, Daniela ^a   Frau, Maddalena ^a   Seddaiu, Maria A ^a   Feo, Francesco ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DIETHYLNITROSAMINE; MYC PROTEIN; PROTEIN P16; PROTEIN P27; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; LIVER CANCER; LIVER CARCINOGENESIS; MALE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RAT; RAT STRAIN; STRAIN DIFFERENCE;

EID: 18544385653     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.33682     Document Type: Article

References (49)

1. Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10
2. Genetic resistance to chemical carcinogen-induced preneoplastic hepatic lesions in DRH strain rats
3. The BN rat strain carries dominant hepatocarcinogen resistance loci
4. Frequent loss of heterozygosity at the Hcr1 (Hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF21 rat strain
5. c-Myc overexpression and amplification correlate with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain
6. c-Myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model
7. Genomewide loss of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allelic imbalances on chromosomes 1, 6, 8, 11, 17, and 20
8. Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain
9. Genetic alterations in liver carcinogenesis: Implications for new preventive and therapeutic strategies
10. Disruption of pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-Myc and Transforming Growth Factor α
11. Mysterious liaisons: The relationship between c-Myc and the cell cycle
12. Making decisions through Myc
13. Regulation of retinoblastoma tumor suppressor protein by cyclin/cdks
14. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression
15. Regulation of E2F1 expression by p130 (Rb2) and D-type cyclin kinase activity
16. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma
17. Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters
18. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinoma
19. Inactivation of p16INK4 in hepatocellular carcinoma
20. Reduced p27KIP1 expression in hepatocellular carcinomas
21. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis
22. Reliable stereological method for estimating the number of microscopic hepatocellular foci from their transections
23. Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: Role of remodeling and apoptosis
24. Report of a workshop on classification of specific hepatocellular lesions in rats
25. Comparative PCR: An improved method to determine gene amplification
26. D-type cyclin-dependent kinase activity in mammalian cells
27. Amplification, rearrangements, and enhanced expression of c-Myc in chemically induced rat liver tumors in vivo and in vitro
28. c-Myc gene amplification during hepatocarcinogenesis by a choline-devoid diet
29. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle
30. Repression of cyclin D1: A novel function of MYC
31. Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27KIP1 and p21CIP1
32. Liver regeneration
33. Dual functions of E2F-1 in transgenic mouse model of liver carcinogenesis
34. Myc and ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
35. Functional roles of E2F in cell cycle regulation
36. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity
37. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes
38. Principles of CDK regulation
39. Hepatocellular carcinoma cell cycle: Study of Long-Evans Cinnamon rats
40. Wilson's disease: A new gene and an animal model for an old disease
41. Inhibitors of mammalian G1 cyclin-dependent kinases
42. Amplification of c-Myc in hepatocellular carcinoma: Correlation with clinicopathologic features, proliferative activity and p53 overexpression
43. Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels
44. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation
45. Deregulated cyclin E induces chromosome instability
46. Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice
47. p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma
48. Polygenic control of susceptibility and resistance to hepatocarcinogenesis
49. Loss of p16INK4 protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression